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Abstract
Glioblastomas represent an important cause of cancer-related
mortality with poor survival. Despite many advances, the
mean survival time has not significantly improved in the last
decades. New experimental approaches have shown tumor
regression after the grafting of neural stem cells and human
mesenchymal stem cells into experimental intracranial glio-
mas of adult rodents. However, the cell source seems to be an
important limitation for autologous transplantation in glio-
blastoma. In the present study, we evaluated the tumor
targeting and antitumor activity of human skin-derived stem
cells (hSDSCs) in human brain tumor models. The hSDSCs
exhibit tumor targeting characteristics in vivo when injected
into the controlateral hemisphere or into the tail vein of mice.
When implanted directly into glioblastomas, hSDSCs distrib-
uted themselves extensively throughout the tumor mass,
reduced tumor vessel density, and decreased angiogenic
sprouts. In addition, transplanted hSDSCs differentiate into
pericyte cell and release high amounts of human transforming
growth factor-B1 with low expression of vascular endothelial
growth factor, which may contribute to the decreased tumor
cell invasion and number of tumor vessels. In long-term
experiments, the hSDSCs were also able to significantly inhibit
tumor growth and to prolong animal survival. Similar
behavior was seen when hSDSCs were implanted into two
different tumor models, the chicken embryo experimental
glioma model and the transgenic Tyrp1-Tag mice. Taken
together, these data validate the use of hSDSCs for targeting
human brain tumors. They may represent therapeutically
effective cells for the treatment of intracranial tumors after
autologous transplantation. [Cancer Res 2007;67(7):3054–63]
Introduction
Brain tumors, such as glioblastoma multiforme, are highly
aggressive tumors and are characterized by marked angiogenesis
and extensive tumor cell invasion into the normal brain
parenchyma (1–3). To date, there are no efficient therapeutics
available for glioblastoma multiforme. Surgical removal of the
tumor, radiotherapy, and chemotherapy, including new drugs, such
as temozolamide, improve survival for a certain period after which
the tumor relapses. Therefore, the need to develop new effective
therapeutic tools is particularly high. Therapeutics for glioblastoma
multiforme ideally should aim to target both the tumor cell and the
tumor vasculature (4–6). Many animal studies have shown that the
tumor vasculature can be selectively targeted without affecting
existing vessels (7, 8). This approach presents some advantages,
one of which is that the tumor vasculature, derived from normal
host cells, is less likely to develop therapeutic resistance (9, 10).
Recently, transplanted neural stem cells (NSCs) have been
recognized for their ability to migrate throughout the central
nervous system (11, 12). The tropism of NSCs for brain tumor can
be used for delivering therapeutic molecules, such as genes,
proteins, peptides, or small chemical molecules (13, 14). However,
their clinical application is limited by ethical and logistic problems
such as their isolation and their immunologic compatibility in
allogenic transplantation. It therefore becomes mandatory to
identify new sources of readily accessible stem cells with similar
tumor targeting properties. Mesenchymal stem cells (MSC) can be
easily isolated from the bone marrow (15, 16) and migrate after
local intracranial delivery to human gliomas (17). Moreover, U87-
MG glioblastomas grown in mice and treated marrow-derived
neural competent cells transduced with soluble platelet-factor-4
(sPF4) showed a decrease in tumor growth (18). We isolated
recently and characterized a multipotent stem cells from human
skin tissue expressing the CD133, a hemapoietic/endothelial
marker (19). These cells could represent a new source of accessible
stem cells for tumor treatment. In this study, we undertook a series
of experiments to investigate the tumor targeting capacity of
human skin-derived stem cells (hSDSCs) in animal models of
human glioblastoma. Our results indicate that hSDSCs indeed
target brain tumors, inhibit tumor growth, and modulate the vessel
architecture within tumors.
Materials and Methods
Cell culture. The human glioblastoma cell line U87-MG [American Type
Culture Collection (ATCC), Manassas, VA] was used in all animal
experiments. U87-MG were cultured in MEM-a (Life Technologies, Inc.,
Grand Island, NY) supplemented with 2 mmol/L L-glutamine, 2 mmol/L
sodium pyruvate, 100 units/mL penicillin, 0.25 Ag/mL streptomycin
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fungizone, and 10% fetal bovine serum (FBS; Life Technologies). Cells were
maintained in T-25 tissue culture flasks in 5% CO2/95% air at 37jC in a
humidified incubator and were routinely passaged at confluency. For the
intracranial transplantation experiments, U87 cells were dispersed with a
0.05% solution of trypsin/EDTA (Life Technologies), washed with PBS, and
adjusted to a final concentration of 5  104cells/10 AL in PBS. The porcine
aortic endothelial cell line stably transfected with KDR (PAE/KDR; ATCC)
was used as control for the migration experiments. These cells were
cultured in Ham’s F-12 medium with 10% FCS and 10 Ag/mL geneticin
(G-418 sulfate). Human adult skin tissues were obtained from 14 healthy
volunteer donors (12–65 years of age) after obtaining informed consent for
the guidelines of the University of Milan Committed on the Use of Human
Subjects in Research. All the experiments were done with pooled cells from
several donors. Skin tissues (ranging in the adult between 5 and 10 mm3)
were dissected carefully, without contamination from other tissues, and
minced into smaller pieces with razor blades. Smaller pieces were washed
thrice with essential balanced salt solution (EBSS) and enzymatically
dissociated by adding 0.2% collagenase type I and 0.1% trypsin for 1 h at
37jC followed by 0.1% DNase for 1 min at room temperature. The tissue cell
extract was filtered with a 70-Am nylon mesh (DAKO, Carpinteria, CA) and
plated in noncoated flask for 24 h. The growth medium used was composed
of DMEM/F-12 (1:1) and 20% FBS, including HEPES buffer (5 mmol/L),
glucose (0.6%), sodium bicarbonate (3 mmol/L), and glutamine (2 mmol/L).
hSDSCs cells were resuspended in PBS, incubated with CD133 (monoclonal
antibody)–conjugated super paramagnetic microbeads (CD133 Isolation kit,
Miltenyi Biotec, Bergisch-Gladbach, Germany), washed, and processed by
using a magnetic-activated cell sorter (MACS; Miltenyi Biotec). After
selection, an aliquot of the CD133-positive cell fraction was analyzed by
cytofluorimetry to assess purity. To verify whether hSDSCs can also
differentiate into pericytes, these cells were plated in EGM2 medium
(Cambrex) enriched with 10% FBS. After 7 days, cultured cells were stained
for pericyte markers as alkaline phosphatase, CD146, NG2, a-smooth
muscle actin (a-SMA), and desmin.
Endothelial progenitor cells (EPC) were obtained by blood-derived
CD133-positive cell sorting for the CD34-APC (Becton Dickinson,
Immunocytometry Systems, San Jose, CA), with a dual laser FACS-Vantage
SE (Becton Dickinson, Immunocytometry Systems), to obtain a purified
CD133-positive/CD34-positive population. Cells were cultured under the
same conditions as described for hSDSCs. For tumor targeting studies, cells
were labeled with PKH26 as described previously (20). For the short- and
long-term transplantation, cells were transduced with a lentivirus express-
ing the green fluorescent protein (GFP) cDNA under the human
phosphoglycerate kinase promoter (21). In all experiments, 30,000 cells
diluted into 5 AL saline solution were injected.
Chick chorio-allantoic membrane experiments. Experimental glioma
growth was obtained after grafting 3 million U87 cells in 20 AL of medium
on the chorio-allantoic membrane (CAM) as described previously (22). For
the first experiment, after 2 days of U87 growth, the tumor received 30,000
hSDSCs (n = 6) labeled with PKH red dye. For the second series of
experiments, 120,000 of hSDSCs PKH red positive (n = 7) were used. Control
experimental tumors were treated with cell-free medium (n = 9). Seven days
after U87 implantation, tumors were removed and frozen in liquid
nitrogen–cooled isopentane. Cryostat sections from frozen tissues embed-
ded in ornithine carbamyl transferase (OCT) were cut into 8-Am serial
sections and processed for immunolabeling.
Animal experiments. For the intracranial glioma model, 6-week-old
nude mice (Charles Rivers Italia, Calco, Italy) received a stereotactical
injection of 50,000 human U87 glioma cells into the left forebrain (2 mm
lateral and 1 mm anterior to bregma, at a 3 mm depth from the skull
surface). For tumor targeting experiments, the right hemisphere was
injected with hSDSCs (n = 5), KDR (n = 5), or EPCs (n = 5) 21 days after
the implantation of the U87 cell line into the controlateral hemisphere.
After 3 and 14 days, mice were sacrificed and their brains were removed,
embedded in OCT, and stored at 70jC. For the homing experiments, we
injected i.v. 120,000 hSDSCs (n = 5) and EPCs (n = 5) into U87 implanted
nude mice and sacrificed them after 21 days. For every experiment, the
control group (n = 4) did not receive cells after tumor implantation. The
short- and long-term experiments were done in two different groups. In
the first group of experiments, the hSDSCs (n = 20) were transplanted
omolaterally into the 5-day implanted tumor. In the second group of
experiments, hSDSCs (n = 32) were transplanted omolaterally 10 days
after U87 cell line implantation. For short-term experiments, all animals
were killed and their brains were removed 21 days after tumor
implantation. For long-term experiments, animals were carefully moni-
tored for the occurrence of any side effects and immediately sacrificed at
the occurrence of any neurologic deficits. Control groups only received
U87 injection (n = 21). Two groups of animal controls were represented by
five males and four females not injected. The Tyrp1-Tag line was obtained
from Dr. F. Beermann (Swiss Institute for Experimental Cancer Research,
Lausanne, Switzerland). Tyrp1-Tag males develop a tumor from the retinal
pigment epithelium and represent a good model for tumor invasion (22).
hSDSCs were transplanted in males (n = 8) and control littermate females
with no tumors (n = 4). All brains were fixed in 5% paraformaldehyde
in PBS for 24 h at 4jC, dehydrated in 30% sucrose in PBS for 24 h at
4jC, embedded in OCT, and stored at 70jC. Brain tissues were cut on
a cryostat into 7-Am serial sections and used for H&E staining or
immunohistochemistry.
Immunohistochemical analysis. Sections were fixed in 80% ethanol for
3 min and then preincubated with 0.1% Triton X-100 and 10% horse serum
for 30 min at room temperature. Primary antibodies were diluted in PBS
containing 1% horse serum and then incubated for 2 h at room
temperature. Polyclonal anti-GFP594 conjugate (GFP594; 1:50; Molecular
Probes) was used to detect hSDSCs and human EPCs after brain
transplantation. Tumor sections were incubated with anti-lamin A/C
(1:100; Novocastra), anti-vimentin (1:100; Chemicon), anti-angiopoietin
2 (Ang2; 1:100; Chemicon), anti-fibronectin (1:100; Sigma-Aldrich, St. Louis,
MO), and anti-collagen type IV (1:100; DAKO). Proliferating cells were
detected by staining with human KI67 (1:100; DAKO). Apoptosis was
detected by using terminal deoxynucleotidyl transferase–mediated dUTP
nick end labeling staining (TUNEL; Roche) as described previously (23). For
detection of pericyte coverage, double labeling experiments were done with
monoclonal anti-CD31 (1:50; Becton Dickinson) and polyclonal anti-desmin
(1:200; DAKO). Tumor vessels were immunostained with anti-CD31 and
anti–von Willebrand factor (1:100; DAKO) or monoclonal anti-laminin
(1:100; Sigma-Aldrich). Monoclonal antibodies anti-CD45 (1:100; RD
Systems) and anti-CD133 (1:100; RD Systems) were used to detect human
stem cells in the transgenic mice. Brain sections were also incubated with
human endothelial markers as Ve-cadherin (1:50; Chemicon), a-SMA (1:100;
Sigma-Aldrich), and angiopoietin 1 (Ang1; 1:100; RD Systems). The sections
were rinsed in PBS and incubated with corresponding secondary antibodies
Alexa Fluor 488, Alexa Fluor 594, or Alexa Fluor 647 (1:200; Molecular
Probes), for 30 min a room temperature. For experimental glioma grown on
the CAM, chick blood vessels were analyzed by using SNA-1 lectin FITC
conjugated (1:200; Vector Laboratories, Burlingame, CA). Cell nuclei were
stained with 4¶,6-diamidino-2-phenylindole (DAPI), and sections were
mounted with ProLong anti-Fade (Molecular Probes) and examined under
a Leica DMIR2 fluorescence microscope. For the immunohistochemical
staining, sections were incubated at room temperature for 20 min with a
solution of methanol containing 0.03% H2O2 and incubated for 30 min with
1% horse serum and then for 1 h with the following antibodies: anti-CD31
(1:50) and anti-desmin (1:100, Novocastra). After a brief rinse with PBS,
sections were incubated with biotinylated secondary antibodies (1:100;
Vector Laboratories), washed, and incubated with the avidin-biotinylated
peroxidase complex (avidin-biotin complex method kit, Vector Laborato-
ries). The staining was visualized by treatment for 10 min in a 0.05%
solution of 3,3¶-diaminobenzidine and 0.01% H2O2 in 0.1 mol/L PBS.
Sections were counterstained with hematoxylin. For all immunostaining,
control reactions were done omitting the primary antibody, which was
substituted by non immune serum.
Fluorescent in situ hybridization. Fluorescent in situ hybridization
analysis was done on frozen brain tissue sections as described previously
(24). The slides were first treated for 30 min with Histochoice Tissue
Fixative (Sigma-Aldrich) and then dehydrated in 70%, 80%, and 95% alcohol.
The denaturation was done at 70jC for 3 min in 70% deionized formamide
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in 2  SSC and slides were dehydrated again at 20jC. The hybridization
was done overnight at 37jC in a moist chamber. A Cy-3–labeled human pan
centromeric probe and FITC-labeled pan centromeric probe were used to
identify human and mouse cells, respectively. The nuclei were counter-
stained with DAPI. Slides were observed using a Leica TCS 4D confocal
microscope.
Western blot. To characterize the effects induced by the injection of
hSDSCs cells, we evaluated the expression of several angiogenic factors by
Western blot with anti-Ang1 (1:100; Santa Cruz Biotechnology, Inc. Santa
Cruz, CA), anti-Ang2 (1:50; Santa Cruz Biotechnology), and anti–platelet-
derived growth factor BB (1:200; Santa Cruz Biotechnology) as described
previously (25).
Statistical analysis. Data are presented as means F SD. Statistical
analysis was carried out by the Student’s t test. We considered probability
(P) values <0.05 as significant.
Results
Effects of hSDSCs on the chicken embryo glioma model. To
characterize the effects of hSDSCs on tumor angiogenesis, we
evaluated these cells in the experimental glioma grown on the
CAM of the chick embryo as described in diagram of Fig. 1A .
In this model, U87 glioma cells form a solid tumor, which
Figure 1. hSDSCs transplantation on a chicken embryo glioma model. Experimental glioma assay. A, 2 d after U87 implantation into CAM, 30,000 and 120,000
hSDSCs were injected on the tumor surface, and 5 d after cell injection, the CAM tissues were removed and frozen in liquid nitrogen–cooled isopentane. Biomicroscopy
showed a progressive tumor vascularization at the surface of both tumors treated with 30,000 and 120,000 hSDSCs. B, 7 d after U87 injection, tortuous vessels,
expressing the laminin antigen (Cy-5), with desmin-positive pericytes (green ), were detected inside the tumor area. C, in these control tumors, only few desmin-positive
pericytes (Cy-5) were found associated to a-SMA-positive vessels (green ). D, after injection, PKH26-positive hSDSCs (red, arrowhead) distributed themselves around
the laminin-positive vessels (Cy-5). E, labeled cells (red ) coexpressing the desmin antigen (Cy-5, arrowhead) were also found associated to a-SMA-positive blood
vessels (green ). F, hSDSCs were also distributed as cellular clusters within the tumor area, coexpressing the PKH26 (red) and human Ve-cadherin (green ),
desmin (green ), or Ang1. G, quantitative analysis of the number of pericytes desmin-positive cells. Data are representative of three experiments (seven eggs per
group). *, P < 0.05; **, P < 0.001, statistical analysis (Student’s two-tailed t test) proved the difference between control tumor and hSDSC-treated tumors.
Cancer Research
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progressively becomes vascularized (22). hSDSCs were labeled
with PKH26 and deposited onto the tumor 2 days after U87
transplantation. After 7 days, tortuous and dilated vessels were
visible at the tumor surface of treated and untreated tumors (data
not shown). Analysis of histologic sections by H&E staining did
not reveal significant differences in size of treated or untreated
tumors (data not shown). Laminin staining (Fig. 1B) was done to
visualize tumor vessel network and only few of them exhibited
desmin-positive associated pericytes. Few desmin-positive peri-
cytes were also observed around SMA-positive vessels (Fig. 1C).
PKH-positive hSDSCs were distributed near and far from the
injection site within and around the tumor in all specimens.
These data indicate that hSDSCs have a high migratory capacity.
After injection, labeled hSDSCs were detected near the tumor
vessels, where some of them, reminiscent of pericytes, coex-
pressed the desmin antigen (Fig. 1D). PKH26/desmin double-
positive cells, reminiscent of pericytes, were also found associated
with SMA-positive tumor vessels (Fig. 1E). However, the total
number of desmin-positive cells was significantly increased in the
center of hSDSC-treated tumors (n = 10) compared with
untreated tumors (n = 10; Fig. 1G). Moreover, injection of hSDSCs
decreased vessel density in treated tumors (vessel density in
control = mean 72.5% F 15.4 SE; vessel density in hSDSCs treated =
mean 41.6% F 11.1 SE, n = 10).
Double-positive hSDSCs were distributed as cellular clusters
around tumor cells, where they coexpressed PKH26 and endothelial
markers, such as the human Ang1 and human Ve-cadherin
(Fig. 1F). These data were also confirmed by immunoblot analysis
of pooled single cells isolated by laser capture microscopy (n =
1,000; data not shown).
Pericyte differentiation of hSDSCs was also obtained by in vitro
experiments as indicated in Materials and Methods. These
experiments revealed a pericyte-like cell population that expressed
NG2 (17F 2.7% of total cells), desmin (25F 4.7% of total cells), and
a-SMA (19 F 6.1% of total cells) after 7 days of differentiation of
hSDSCs.
Figure 2. Tumor target ability of hSDSCs.
A, below each photograph is a
schematized composite image of the
experimental model. The U87 human cells
were implanted in the frontal lobe of nude
mice and PKH26-positive hSDSCs were
injected into the controlateral hemisphere.
Left, red PKH26-positive hSDSCs
counterstained with DAPI at the site of
injection; right, several PKH26-positive red
cells within the tumor area 14 d after the
injection. B, to determine the tumor homing
capacity, the transduced GFP594-positive
hSDSCs (left) were injected into the tail
vein of nude mice, in which a U87
glioblastoma had been established 14 d
before. Right, a cluster of injected
GFP594-positive hSDSCs within the tumor
area 21 d after their i.v. transplantation.
C, quantification of the i.v. injected
GFP594-positive hSDSCs in different
tissues, such as lungs, kidneys, liver, and
brain tumor. D, quantitative analysis of
the percentage of GFP594-positive cells
associated and not associated to the
tumor vessels. E, several GFP594-positive
cells that reached the brain tumor
coexpressed the human Ang1, CD31,
and a-SMA endothelial markers (green ).
Data are representative of three
experiments (five mice per group).
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hSDSCs in vivo migrated toward glioblastoma after contro-
lateral injection. To evaluate the tumor targeting properties of
hSDSCs in vivo , intracranial xenografts of human U87 were
established in the frontal lobe of nude mice as indicated in Materials
and Methods. Twenty-one days after tumor cell implantation,
hSDSCs (3  104 suspended in 10 AL PBS) were injected into the
controlateral hemisphere of the same animal. As control, two groups
of nude mice received respectively a controlateral injection of EPCs
or porcine aortic endothelial cells transfected with cDNA of vascular
endothelial growth factor (VEGF) receptor-2 (KDR cells). Before
injection, cells were labeled with PHK26. Animals were killed 3 and
14 days after cell injection and brains were analyzed. Three days after
cell injection, clusters of PKH-positive hSDSCs were seen exclusively
at the injection site. However, 14 days after cell injection, hSDSC
PKH-positive cells were detected in the controlateral hemisphere
and within the tumor (Fig. 2A). This indicates that hSDSCs migrated
Figure 3. hSDSCs effect on tumor volume
and animal survival. A, 21 days after
hSDSCs transplantation of the animals, the
tumor volume was calculated. The highest
tumor growth inhibition was observed when
we injected hSDSCs. *, P < 0.05. Columns,
percentage of untreated tumor; bars, SE
(referred as 100%). PBS-treated tumors
and tumors injected with EP cells
were also used as control. Data are
representative of 20 mice for each group.
Tumor volume was estimated using the
formula for ellipsoid (width2  length) / 2.
B, Kaplan-Meier survival curves. In
long-term experiments, the brain tissues
were harvested at the onset of signs of
distress or neurologic deficits. The longest
survival was observed when hSDSCs
were injected 5 d (5d) after U87
transplantation. Data are representative
of 20 mice for each group. Day 0
corresponds to the day of tumor cell
implantation. C, histopathologic analysis
of survival of treated animals after hSDSCs
injection. The immunostaining with
antibodies against CD31 was done to
analyze the tumor vascular network: in the
group of animals that received hSDSCs
5 d after the U87 implantation, the vessels
appeared smaller with less capillary
sprouts than the group treated 10 days
(10d ) after U87 implantation. Only in the
survival animals that received the hSDSCs
5 d after the U87 implantation, we observed
a reduction in the proliferation index, as
shown by KI67 staining. In all survival
animals, the apoptotic process, visualized
by in situ labeling fragmented DNA
(TUNEL), seemed higher than the
untreated U87 implanted animals. The
individual satellite area (D ) was reduced
compared with untreated tumor control.
*, P < 0.05. The values were expressed as
mean of three independent microscopic
fields for tissue section. Magnification,
40. The ELISA analysis from the tumor
extracts (E ) shows high expression of
human TGF-h1 in hSDSC-transplanted
tumors. Importantly, the VEGF expression
is lower than untreated tumor control after
hSDSCs transplantation (E). Data are
representative of 24 mice from each group.
*, P < 0.05; **, P < 0.001, statistical
analysis (Student’s two-tailed t test) proved
the difference between control tumor and
hSDSCs treated tumors.
Cancer Research
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from the injection side across the corpus callosum and to the tumor.
On the contrary, EPCs or KDR cells fail to migrate away from the
injection site (data not shown).
hSDSCs target experimental glioblastoma after i.v. injec-
tion. To further determine the tumor targeting ability of hSDSCs,
cells were injected into the tail vein of nude mice, in which U87
glioblastoma had been established 14 days before in the frontal
lobe. As a control, we also injected EPCs. To distinguish injected
cells from human cells migrating away from the tumor mass, they
were transduced with a vector containing the GFP cDNA before
injection (Fig. 2B). Twenty-one days after tumor cell implantation,
a small percentage of injected hSDSCs (ffi 5%) reached the brain
tumor, whereas most cells that had probably passed through the
capillary network ended in the venous circulation and were
trapped in filter organs (Fig. 2C). hSDSCs and EPCs (data not
shown) migrated to the tumor and interspersed throughout the
tumor (Fig. 2B). Few GFP-positive hSDSCs were localized in the
interface of the tumor mass, where they remained CD133 positive
(data not shown). Throughout the tumor mass, we found hSDSCs
expressing Ang1, CD31, and a-SMA (Fig. 2E). The percentage of
hSDSCs associated to laminin-positive vessels was about 61 F 9%
(Fig. 2D). Similarly, GFP-positive EPCs, when injected in mice, also
expressed endothelial cell markers within the center of the tumor
(data not shown).
Effects of hSDSCs after intratumoral cell implantation. For
these experiments, cells were injected 5 and 10 days after U87
implantation homolaterally to the tumor. Brains were analyzed
after 21 days (short-term experiments) or in long-term experiments
for survival. After 21 days, a reduction of 40% in tumor size was
seen in mice homolaterally injected with hSDSCs (Fig. 3A). In long-
term experiments, untreated animals showed a survival of 50%
after 28 days. Animals treated with hSDSCs reached 80% survival at
120 days (Fig. 3B). The majority of hSDSCs were interspersed
throughout the tumor and only few cells were able to migrated to
the periphery of the tumor mass (Fig. 4A). Angiogenesis in tumors
was estimated by CD31 and desmin staining (Figs. 3C and 4B and
D). In control mice implanted with tumor cells alone, large
tortuous vessels with irregular diameter were detected (Fig. 4C).
Figure 4. Characterization of tumors injected with GFP-positive hSDSCs and controls. A, schematized composite image of hSDSC implantation in U87 brain tumor
in mice. Five days after tumor implantation, 30,000 GFP-positive hSDSCs were injected inside the tumor and visualized after 21 d (left). B and C, quantification of
desmin-, CD31-, TUNEL-positive cells and vessel diameter in control or hSDSC-treated tumors. The number of desmin-, CD31-, and TUNEL-positive cells was
expressed as mean of six independent microscopic fields for tissue section. Magnification, 40. *, P < 0.05; **, P < 0.001, statistical significance, Student’s two-tailed
t test. Tumor vessel diameter quantification (C ). The values of vessel diameter, expressed in micrometer, were obtained using NIH Image 63 and GraphPad Prism
version (GraphPad Software, San Diego, CA): for each experimental group, individual vessel diameter is displayed as the same symbol: square, control tumor; triangle,
hSDSC-treated tumors (5 d); inverse triangle, hSDSC-treated tumors (10 d). D, immunofluorescent images after double labeling of control (CTR ) or hSDSC-treated
tumors. Slides from control or hSDSC-treated tumors are double labeled with antibody against laminin/collagen IV, CD31/desmin, or K67/desmin and analyzed by
confocal microscopy. The staining for type IV collagen showed a reduced expression in hSDSC-treated tumors compared with control tumors. Staining for desmin
expression revealed a reduced number of pericytes within and around the tumor vessels in control tumors (arrowhead) versus hSDSC-treated tumors (arrowhead).
None of them was Ki67 positive (arrowhead). Desmin-positive cells coexpressing the Ki67 antigen were seen after hSDSCs transplantation (arrowhead). Data are
representative of four experiments (24 mice per group).
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In tumors of mice injected with hSDSCs, vessel number was
decreased with smaller vessels of less variable size (Figs. 3C and
4B and C). A more detailed analysis revealed that there was less
capillary sprouts and a reduction of teleangiectatic or dilated
vessels in the animals that received the hSDSCs 5 days after U87
implantation (data not shown). Apoptotic indexes, quantified
in situ by labeling fragmented DNA (TUNEL), were increased in
tumors of animals that received hSDSCs 5 or 10 days after U87
implantation (Figs. 3C and 4B). Survival animals that received the
hSDSCs 5 days after the U87 implantation showed a reduction in
the proliferation index, as shown by KI67 staining (Fig. 3C).
Double labeling with anti-desmin and CD31 antibodies was done
to visualize vessel-associated pericytes. In control tumors, only
few vessels exhibited vessel-associated pericytes (Fig. 4B and D).
In tumors from mice injected with hSDSCs, the percentage of
desmin-positive cells was increased (80% F 12.5 SE in SDSCs-
injected mice versus 51.4% F 9.8 SE in control mice; Fig. 4B and
D). The increase of desmin-positive cells was accompanied by a
reduction of CD31-positive vessels (Fig. 4B). Double staining for
desmin and human KI67 in tumors from hSDSCs-injected mice
Figure 5. hSDSC implantation in tumors from Tyrp1-Tag transgenic mice. The hSDSCs were injected into the brains of tumor-bearing Tyrp1-Tag mice. A, schematic
depiction of mouse brain showing the location of sections (I–V ) used for the H&E staining of the brain of treated Tyrp1-Tag mice 45 days after the injections of
hSDSCs. Right, H&E staining of tumor area of sections I to V with the reduction of the tumor size and invasion of treated Tyrp1-Tag mice (hSDSCs ) versus control
untreated tumor (CTR ). B and C, two different magnification of DAPI staining for the selected areas of (E). IN and OUT, the center and the border of the tumor,
respectively. D, the number of CD31-positive (total vessels) and CD31/lamin A/C double-positive vessels (human vessels). n = 6 independent fields. **, P < 0.001,
statistical significance, Student’s two-tailed t test. E, implanted hSDSCs were revealed by specific antihuman lamin A/C (red) and examined for the expression
of human Ang1, CD31, human Ve-cadherin, and a-SMA (all shown in green ) at the center (IN) and at the border of the tumor (OUT ). Immunofluorescence analysis
showed CD31 and human Ve-cadherin expression in hSDSCs-treated tumors. hSDSCs express human Ang1 in the center of the tumor mass. Data are
representative of two experiments (five mice per group).
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revealed the presence of few proliferating pericytes (Fig. 4B and
D). Furthermore, staining for type IV collagen showed a reduced
expression in hSDSCs-treated tumors compared with control
tumors (Fig. 4D).
It is important to note that, in all experimental groups, injected
cells never became tumorigenic. To show this behavior, for each
experimental group, nude mice were engrafted with only human
stem cells, and animals were sacrificed after 21 (as in short-term
experiments) and 120 days (the longest survival observed in long-
term experiments). In these experiments, injected hSDSCs never
formed a nodule or a tumoral mass and, as recently described (19),
these cells were localized as a small clusters to the host vessels and
near the ventricular zone.
Intratumoral gliosis in SDSC-treated tumors is correlated
to high expression of human transforming growth factor-B1.
We observed a less invasive pattern of tumor growth in mice
treated with hSDSCs compared with control groups. In fact, a
reduced number of satellite tumor clustered around the primary
was observed after hSDSCs (Fig. 3D). These satellites contained
central vessel cores and their quantification revealed that their
frequency was less in hSDSCs treated tumors than in U87-derived
controls (Fig. 3D). We hypothesized that hSDSCs would induce a
gliotic reaction and allowing the reduction of satellite tumor
outgrowth. Gliotic reaction was quantified on histologic sections
after staining for Azan Mallory, which labels fibrosis (data not
shown). Sections from hSDSC-treated tumors revealed variable
intratumoral gliotic areas around satellites (ranging from 9% to
1% of tumor volume) but the increase of these areas compared
with untreated controls was not statistically significant (data not
shown). One potential source for the increased gliosis and
decreased number of vessels within the U87-derived tumor could
be the secretion of human transforming growth factor-h (TGF-h)
1 by the hSDSCs. To screen for presence of secreted human TGF-
h1, we did ELISA analysis from the supernatants of hSDSCs and
from the transplanted tumors. ELISA analysis shows the presence
of human TGF-h1 in both U87 (455.2 F 103 SE pg/mL) and
hSDSCs (308.7 F 60 SE pg/mL) conditioned medium (data not
shown). Importantly, we observed higher levels of TGF-h1
expression in transplanted tumors than in hSDSCs conditioned
medium, up to 2- to 3-fold higher than in conditioned medium of
hSDSCs or U87 cells (Fig. 3E). We also found higher expression of
human TGF-h1 in tumors implanted with hSDSCs than in control
tumors not implanted with hSDSCs (Fig. 3E). Moreover, VEGF
expression was absent in hSDSCs conditioned medium and lower
in tumors implanted with hSDSCs than in untreated control
tumors (Fig. 3E). The ratio of TGF-h1/VEGF is highly in favor of
TGF-h1 in both hSDSCs supernatants and tumor extracts. These
findings suggested that transplanted hSDSCs release high
amounts of human TGF-h1 with low expression of VEGF, which
may contribute to the decreased tumor cell invasion and number
of tumor vessels.
hSDSCs reduced tumor growth after injection into the
brain of Tyrp1-Tag transgenic mouse. To confirm the capacity
of hSDSCs to reduce the brain tumor outgrowth, we investigated
their tumor targeting and antitumor activity in the Tyrp1-Tag
transgenic mouse model. These mice develop highly aggressive
tumors from the retinal pigmented epithelium of the eye that
migrate along the optic nerve and invade the brain (26–28). These
tumors are highly vascularized with blood vessels of heteroge-
neous size and shape and a discontinuous CD31-positive cell
coverage. Male but not female mice develop tumors. PKH26-
labeled hSDSCs were injected into the cerebral hemisphere of
male and females mice at postnatal day 21. Brains of tumor-
bearing (males) or control mice ( females) were analyzed at
postnatal day 45. In control mice, clusters of PKH red–positive
cells coexpressing the CD31 were found adjacent to reactive host
GFAP-positive astrocytes (data not shown). We also found several
PKH red–positive cells coexpressing desmin associated with brain
blood vessels (data not shown). These data suggested vessel
differentiation ability of hSDSCs when injected into the brain. In
tumor-bearing male mice, hSDSCs injection was associated with
an 80% F 11 SE reduction of brain tumor area (analyzed from
serial H&E-stained serial sections; n = 10; Fig. 5A and D). PKH
red–positive cells were found in the periphery and within the
tumor mass (data not shown). Furthermore, implanted cells were
detected using a specific human lamin A/C antibody that only
recognizes human cells (Fig. 5). Lamin A/C–positive hSDSCs were
found at the interface of the tumor mass expressing the CD133
stem cell marker. hSDSCs around the tumor, as evidenced by
counting lamin A/C–positive cells, were abundantly detected.
Moreover, throughout the i.c. tumor mass, hSDSCs were found,
which also expressed human Ang1 and Ve-cadherin (Fig. 5E).
Around vessels, human CD31- and SMA-positive cells were also
detected, whereas no expression of human Ang1 was seen (Fig. 5E).
We also counted the number of CD31-positive vessels and the
number of CD31/lamin A/C double-positive cells within the tumor
mass. These data indicated a decrease of CD31-positive vessels
after hSDSCs injection. However, the number of vessels of human
origin (CD31/lamin A/C double-positive vessels) was higher than
vessels expressing murine CD31 only (Fig. 5D). Furthermore,
injection of hSDSCs was significantly associated with a decrease
in the ability of tumor cells to invade normal brain (data not
shown).
Discussion
In this study, we have evaluated the effects of hSDSCs on brain
tumor targeting and development using three different experi-
mental systems, the experimental glioma in the chicken CAM,
U87 xenografts and the Tyrp-1Tag transgenic mice. These studies
indicate that hSDSCs have a high capacity to migrate around and
into experimental tumors, to partially acquire a vascular
phenotype, and to impair tumor development by decreasing
tumor-associated angiogenesis and invasion and by inducing
tumor gliosis. The high migratory capacity of hSDSCs was first
evidenced in the experimental glioma in the chicken CAM. This
model mimics glioma development as it happens in patients
within a short time-frame and has been validated by gene
profiling studies (22). In these experiments, hSDSCs, deposited on
the top of the glioma after 2 days of glioma development, were
able to migrate around and inside the tumor. When injected
controlaterally or i.v. in tumor-bearing nude mice, hSDSCs are
able to localize into and around experimental tumors. To
reinforce this contention, we have used the transgenic Tyrp-Tag
mice that develop a highly aggressive tumor derived from the
RPE that invades the brain. In this experimental setting, hSDSC
cell injected along the optic nerve, also localize around and
within the tumor mass. This indicates that the capacity for
integration into tumors is an intrinsic property of these stem
cells as it has been described previously for other types of stem
cells (11, 15, 16). This is also in agreement with initial work from
our group that showed high migratory capacity of hSDSCs into
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the adult mouse brain (19). By combining the use of antibodies
against human lamin A/C and labeled stem cells, or of stem cells
transduced with GFP, it was possible to track the fate of injected
cells. This method unambiguously recognizes that a fraction of
transplanted cells partially localizes to CD31-positive tumor
vessels.
hSDSCs exhibit vascular cell differentiation capacity when
localized into the tumor tissue. First, labeling with anti-CD31 of a
fraction of hSDSCs, localized to tumor blood vessels, indicates
ability to differentiate into endothelial cells. This agrees with
previous results that showed endothelial cell differentiation
capacity of hSDSCs when injected into the normal mouse brain
(19). Second, hSDSCs also exhibit pericyte/stroma cell differenti-
ation ability in vitro and when implanted into tumor tissue in the
brain. For example, hSDSCs exhibit pericyte differentiation capacity
in culture in the presence of pericyte differentiation medium.
Furthermore, only in nude mice engrafted with U87 glioma and
injected with hSDSCs, several human lamin A/C (that is only
expressed in human cells)–positive cells also expressed desmin and
SMA. It is, at present, not clear whether hSDSCs significantly
contribute to an increase in pericyte recruitment through its
differentiation capacity. In addition, hSDSCs may release pericyte
attraction factors, such as TGF-h (see below), and thus indirectly
contribute to pericyte recruitment. Nevertheless, the vessel
architecture after hSDSC treatment is modified and is composed
of small elongated vessels, with small diameter, and better pericyte
coverage, findings consistent with a normalization of tumor vessel
architecture.
Tumor growth and invasion are strongly inhibited in the nude
mice glioma model and the Tyrp-Tag mice but not in the
experimental glioma in the CAM. The lack of effect on these
variables is probably due to the short-time interval required for
CAM experiments, which will mask potential inhibitory effects.
Inhibition of tumor cell invasion, evidenced by a reduction of
tumor satellites in hSDSC-treated tumors, was associated with
an increase of expression of human TGF-h1. It is interesting to
note that hSDSCs exhibit high capacity to proliferate in
response to TGF-h1 (29). Although known for its growth-
inhibitory function in epithelial tissues, high levels of TGF-h1
were correlated with tumor-suppressive function (30–33).
Although the levels of TGF-h1 were highly increased in tumors
treated with hSDSCs, much lower VEGF levels were observed.
This indicates that the balance between VEGF and TGF-h is in
favor of TGF-h that may counteract the effect of VEGF. In fact,
TGF-h increases the expression of protease inhibitors, such as
plasminogen activator inhibitor-1, thus counteracting extracel-
lular proteolysis, thus inhibiting fibrin and collagen I degrada-
tion (34). On the contrary, VEGF favors extracellular proteolysis.
Taken together, these results indicate that hSDSCs modify the
growth factors repertoire in treated tumors leading to impair-
ment of tumor development through the inhibition of angio-
genesis and tumor cell invasion.
One can only speculate about the increase in survival when
hSDSCs are injected 5 days after tumor implantation but not
10 days after tumor implantation. At 5 days, the effect of hSDSCs
on tumor development occurs at an early phase of tumor
expansion when tumor cells are bearly established in their tumor
microenvironment. Apparently, hSDSCs are blocking signaling
events that are critical for tumor expansion at this early phase of
tumor development. This situation is somehow comparable with
the effect of some antiangiogenesis molecules in experimental
tumors where they are improving overall survival only when given
from the beginning of the experiment (‘‘angioprevention and
angioinhibition’’) but not when they are administered at a later
time point. To ascertain that the effects of hSDSCs were not
dependent on the immunodeficient background of nude mice,
experiments with immunocompetent Tyrp-Tag mice were done.
Similarly, inhibition of tumor development was also observed in
these mice. The antitumor activity is most likely not due to an
activation of the antitumor immunoresponse in these mice and
this for several reasons. First, we did not detect infiltration of
immune cells in the vicinity of implanted hSDSCs. Second, low
immunogenicity and absence of rejection as allowgrafts of stem
cells, such as NSCs, were observed (35, 36). Third, we expanded
hSDSCs using stem cell mitogens as indicated in Material and
Methods. It has been reported that immunogenicity of porcine
neural cell suspensions used for i.c. xenotransplantation is
reduced when stem cell mitogens are used to expand precursor
cells (37). Several arguments are in favor of an advantage of the
use of hSDSCs when compared with other cell therapy–based
strategies. Previous studies have shown the capability of NSCs
obtained from neonatal mouse cerebellar germinal zone to target
the tumor. Aboody et al. (12) showed that transplanted NSCs have
the ability to migrate toward an intracranial tumor cell mass.
This ability of stem cells to migrate toward a tumor mass was
seen when injected at intracranial sites distant from the tumor
and even after injection into the tail vein. This extensive
migratory capacity of NSCs is retained in the tumor environment
and may be advantageously applied both to delivering therapeutic
molecules to the primary tumor and to distant sites from the
central tumor mass. Recently, Benedetti et al. (11) reported that
NSCs genetically modified to produce interleukin-4 could
promote tumor regression and prolonged survival in mice that
have been injected intracranially with the GL261 mouse glioma
cell line. However, the inaccessibility of NSCs severely limits their
clinical use. Bone marrow–derived MSCs represent an alternative
source in the treatment of glioblastoma. This renewable
population is particularly attractive for clinical uses because it
can be easily obtained from the same patients and be used in allo-
genic transplantation, without immunosuppression, sometimes
particularly problematic for the patient. Moreover, Nakamizo
et al. (17) showed that human bone marrow MSCs migrated
toward glioma after intracranial and intravascular injection.
However, only engineered human MSCs (hMSC) have shown
therapeutic advantages. After the intracranial injection of hMSCs
transfected with an adenoviral vector containing the c-DNA of
INF-b gene, treated animals had a significantly extended survival.
On the contrary, control animals that received control hMSC–h-
galactosidase had a shorter survival times than animals who
received only the PBS solution. In fact, hMSCs may integrate into
the glioblastoma and contribute to the mesenchymal elements of
the tumors. It has been shown that bone marrow also represents an
important source of EPCs (38). After injection, EPCs showed a high
migratory capacity and presented a high tropism for the neo-
vasculature, as shown in animal models of ischemia and of solid
tumors (23, 39). Otherwise, when injected into animal tumor
models, EPCs can incorporate themselves into the host vessels and
increase the angiogenesis, with a consequent increase of blood
supply, crucial for the tumor growth and the metastasis. However,
when injected into the brain, EPCs are not able to migrate toward
brain tumors in experimental brain tumor models (our observa-
tions in this study). hSDSCs have the advantages but not the
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disadvantages of the cell therapy–based strategies described above.
hSDSCs are an easily accessible cell population for autologous
transplantation and have a high migratory capacity toward brain
tumors. They are easily expandable in vitro and f1,500,000 cells
can be obtained after the third passage. They have differentiation
capacity and are able to localize around the tumor and to migrate
into the tumor when injected both into the brain and i.v. They can
be transduced with vectors encoding for antitumor molecules (i.e.,
antiangiogenesis, anti-invasion, or proapoptotic/cytotoxic mole-
cules). Thus, they constitute an ideal source for the development of
novel cell-based therapies. Taken together, our results indicate that
hSDSCs target brain tumors and have significant effects on brain
tumor development and animal survival. HSDSCs constitute an ideal
source for autologous transplantation in patients with glioblastoma
and thusmay help to overcome the limitations of other cell therapy–
based approaches.
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